drugset
drugset / Trial / NCT06087731

Efficacy and Safety of Tocilizumab for TAO

NCT06087731 ↗

Phase 2 Withdrawn Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

Timeline

Start
2023-09-23
Primary completion
2023-09-23
Completion
2023-09-23

Outcome

Outcome not reported

Stopped: “For some personal reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg —

Indications

disease of orbital part of eye adnexa